Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment

Glaukos Corporation (GKOS) is up 7.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be investor focus on Epioxa’s new permanent J-code becoming effective on July 1, 2026, a reimbursement milestone that can make payment and claims processing easier over time. This could also be because Glaukos has recently paired that market-access progress with strong commercial momentum and another pipeline update, giving traders several reasons to lean bullish.

Details:

Glaukos said CMS assigned Epioxa a permanent HCPCS J-code, J2789, with an effective date of July 1, 2026, and the company described it as an important step toward expanding payer coverage and patient access.

In its first-quarter 2026 results, Glaukos posted record net sales of $150.6 million, up 41% year over year, and raised full-year 2026 revenue guidance to $620 million to $635 million.

Management has highlighted iDose TR and Epioxa as two major growth drivers, which may be reinforcing optimism as Epioxa moves deeper into its commercial rollout.

Glaukos also announced on June 25 that it completed patient enrollment in its Phase 2 study of GLK-321 for Demodex blepharitis, adding another recent pipeline milestone.

Sources:

Glaukos, Glaukos

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GKOS Insider Trading Activity

$GKOS insiders have traded $GKOS stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.

Here’s a breakdown of recent trading of $GKOS stock by insiders over the last 6 months:

THOMAS WILLIAM BURNS (CHAIRMAN & CEO) has made 0 purchases and 2 sales selling 275,000 shares for an estimated $31,625,000.
JOSEPH E GILLIAM (PRESIDENT & COO) has made 0 purchases and 6 sales selling 34,573 shares for an estimated $4,711,062.
MARC STAPLEY has made 0 purchases and 5 sales selling 15,000 shares for an estimated $1,915,576.
ALEX R. THURMAN (SVP & CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 14,657 shares for an estimated $1,889,359.
AIMEE S WEISNER has made 0 purchases and 4 sales selling 15,000 shares for an estimated $1,760,761.
GILBERT H KLIMAN has made 0 purchases and 2 sales selling 10,000 shares for an estimated $1,378,800.
TOMAS NAVRATIL (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 8 sales selling 4,661 shares for an estimated $548,108.
LEANA WEN sold 1,700 shares for an estimated $243,695

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$GKOS Hedge Fund Activity

We have seen 138 institutional investors add shares of $GKOS stock to their portfolio, and 148 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 1,419,970 shares (+5267.7%) to their portfolio in Q1 2026, for an estimated $152,873,970
AMERIPRISE FINANCIAL INC removed 493,520 shares (-23.5%) from their portfolio in Q1 2026, for an estimated $53,132,363
DRIEHAUS CAPITAL MANAGEMENT LLC added 487,912 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,528,605
UBS GROUP AG removed 487,542 shares (-55.8%) from their portfolio in Q1 2026, for an estimated $52,488,771
JENNISON ASSOCIATES LLC added 487,020 shares (+inf%) to their portfolio in Q1 2026, for an estimated $52,432,573
WESTFIELD CAPITAL MANAGEMENT CO LP added 482,219 shares (+inf%) to their portfolio in Q1 2026, for an estimated $51,915,697
MILLENNIUM MANAGEMENT LLC removed 436,003 shares (-27.1%) from their portfolio in Q1 2026, for an estimated $46,940,082

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GKOS Government Contracts

We have seen $201,070 of award payments to $GKOS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TRAVOPROST 75MCG: $169,104
IDOSE TRAVOPROST 75MCG IMPLANT: $21,310
IDOSE TR 75 MGC IMPLANT: $10,655

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$GKOS Analyst Ratings

Wall Street analysts have issued reports on $GKOS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/10/2026

To track analyst ratings and price targets for $GKOS, check out Quiver Quantitative's $GKOS forecast page.

$GKOS Price Targets

Multiple analysts have issued price targets for $GKOS recently. We have seen 7 analysts offer price targets for $GKOS in the last 6 months, with a median target of $160.0.

Here are some recent targets:

Adam Maeder from Piper Sandler set a target price of $165.0 on 07/01/2026
David Saxon from Needham set a target price of $150.0 on 06/17/2026
Joanne Wuensch from Citigroup set a target price of $162.0 on 06/11/2026
Ryan Zimmerman from BTIG set a target price of $162.0 on 06/10/2026
Allen Gong from JP Morgan set a target price of $140.0 on 04/30/2026
Larry Biegelsen from Wells Fargo set a target price of $138.0 on 04/30/2026
Thomas Stephan from Stifel set a target price of $160.0 on 01/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.